{"id":744373,"date":"2023-03-31T16:30:29","date_gmt":"2023-03-31T20:30:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/obseva-files-year-end-2022-financial-statements\/"},"modified":"2023-03-31T16:30:29","modified_gmt":"2023-03-31T20:30:29","slug":"obseva-files-year-end-2022-financial-statements","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/obseva-files-year-end-2022-financial-statements\/","title":{"rendered":"ObsEva Files Year End 2022 Financial Statements"},"content":{"rendered":"
\n

\n ObsEva <\/strong>
\n Files<\/strong>
\n Year End 2022 Financial <\/strong>
\n Statements<\/strong>\n <\/p>\n

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange<\/p>\n

\n GENEVA, Switzerland \u2013 <\/strong>
\n March <\/strong>
\n 31<\/strong>
\n , 2023 <\/strong>\u2013 ObsEva SA (<\/strong>SIX: OBSN \/ OTC<\/strong> Pink Market<\/strong>: OBSVF<\/strong>), <\/strong>a biopharmaceutical company developing and commercializing novel therapies to improve women\u2019s health, today published its U.S. Annual Report on Form 10-K for Fiscal Year 2022, including the U.S. GAAP financial results for year-end 2022. The U.S. Annual Report on Form 10-K can be accessed in the financial section of the Company\u2019s website, here<\/a> or directly via the link here<\/a>.<\/p>\n

ObsEva expects to publish its Swiss Annual Report to Shareholders, including the financial results for year end 2022 in IFRS, in the week commencing April 24, 2023.<\/p>\n

\n About ObsEva<\/strong>
\n
ObsEva is a biopharmaceutical company developing novel therapies to improve women\u2019s reproductive health and pregnancy. ObsEva has established a development program focused on improving in vitro fertilization success rates. ObsEva is listed on the SIX Swiss Exchange where it is traded under the ticker symbol \u201cOBSN\u201d and on the OTC Pink Market under the ticker symbol \u201cOBSVF\u201d. For more information, please visit www.ObsEva.com<\/a><\/p>\n

\n For further information, please contact: <\/strong>\n <\/p>\n

\n CEO Office contact<\/strong>
\n
Shauna Dillon
shauna.dillon@obseva.ch<\/a>
+41 22 552 1550<\/p>\n

\n Investor Contact<\/strong>
\n
Will Brown
will.brown@obseva.com <\/a>
+1 (334) 313-2319<\/p>\n

###<\/p>\n

\u00a0<\/p>\n

\u00a0<\/p>\n

\n Attachment<\/strong>\n <\/p>\n